Key facts
- This page summarizes Sam Ropp's Form 4 filing for Singular Genomics Systems, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Aug 2023, 16:31.
Sam Ropp - 15 Aug 2023 Form 4 Insider Report for Singular Genomics Systems, Inc.
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- N/A
- Reported as of
- 15 Aug 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Aug 2023, 16:31:04 UTC
- Prior SEC filing
- 20 Jun 2023
- Next SEC filing
- 15 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dalen Meeter, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sam Ropp filed Form 4 for Singular Genomics Systems, Inc. on 17 Aug 2023.
Change
- Previous filing in this sequence was filed on 20 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OMIC
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 15 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $0.5355
- Footnotes
- F1
OMIC
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 15 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $0.5355
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option shares vest and become exercisable in 48 equal monthly installments measured from August 15, 2023, subject to the Reporting Person's continuous service with the Issuer.
Footnote F2
Subject to the achievement of certain performance targets by December 31, 2023, the Reporting Person may earn up to 100,000 stock options pursuant to this award. Any stock options earned will vest 25% on August 15, 2024, and the remaining option shares will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer.